Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

65.99 -0.64 (-0.96%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,458,383
Open 66.85
Bid (Size) 65.62 (6)
Ask (Size) 66.90 (2)
Prev. Close 66.63
Today's Range 65.64 - 66.85
52wk Range 52.65 - 72.12
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Is Johnson & Johnson Still a Good Dividend Stock to Buy?
A disappointing fourth-quarter performance has some investors worried about the giant healthcare conglomerate's outlook. 
Via The Motley Fool
AZN Stock Under Pressure
Shares in UK-headquartered AstraZeneca are back under heavy selling pressure on Monday as the stock extends recent losses. 
Via Talk Markets

Performance

YTD
-4.82%
-4.82%
1 Month
-2.86%
-2.86%
3 Month
+14.55%
+14.55%
6 Month
-1.09%
-1.09%
1 Year
+15.53%
+15.53%

More News

Read More
AstraZeneca Begins Tender Offer to Acquire CinCor Pharma, Inc.
From AstraZeneca
Via Business Wire
The Top Healthcare Stocks to Buy With $100
Via The Motley Fool
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Paya Holdings Inc. (Nasdaq – PAYA), CinCor Pharma, Inc. (Nasdaq – CINC), Albireo (Nasdaq – ALBO), Duck Creek Technologies (Nasdaq - DCT)
From Brodsky & Smith LLC
Via Globe NewsWire
Pharmaceutical Stocks Pfizer, GSK, Moderna Come Close To Cracking A Multibillion-Dollar RSV Vaccine Market
Via Investor's Business Daily
AstraZeneca’s Next “Wonder Drug”
Via Talk Markets
Initiatives For Development of Gamma Delta T Cell Therapies Driven by Large Number of Clinical Trials
Via FinancialNewsMedia
Exposures COVID-19 Product Safety
AbbVie Stock: Dividend King ABBV Overview
Via MarketBeat
HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China
From HUTCHMED (China) Limited
Via Globe NewsWire
Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock?
Via MarketBeat
Topics Stocks
Exposures US Equities
Week In Review: Qitan Raises $101 Million For Nanopore Sequencing Devices
Via Talk Markets
The Viral “Tripledemic” Opportunity
Via Talk Markets
3 Growth Stocks Poised for Huge Gains in 2023
Via The Motley Fool
Why These Two Biotech Stocks Blasted Higher This Week
Via The Motley Fool
Stock Market Rally Gains Steam As Inflation Cools; Tesla Price Cuts, Big Earnings In Focus: Weekly Review
Via Investor's Business Daily
Could This New Drug Launch Be a Hit for Viatris?
Via The Motley Fool
AstraZeneca's New Asthma Treatment for Adults Gets Green Light from FDA
Via Benzinga
AIRSUPRA™ (PT027) approved in the US for asthma
From AstraZeneca
Via Business Wire
AstraZeneca Stock Nabs Breakout After $1.8 Billion CinCor Buyout
Via Investor's Business Daily
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Paya Holdings Inc. (Nasdaq – PAYA), CinCor Pharma, Inc. (Nasdaq – CINC), Albireo (Nasdaq – ALBO), Duck Creek Technologies (Nasdaq - DCT)
From Brodsky & Smith LLC
Via Globe NewsWire
CinCor Pharma (NASDAQ: CINC) Enters Into Agreement to be Acquired by AstraZeneca (NASDAQ: AZN) for $1.3 Billion
Via Spotlight Growth
AstraZeneca To Acquire Blood-Pressure Drugmaker In $1.8 Billion Deal
Via Investor's Business Daily
Why Is CinCor (CINC) Stock Up 138% Today?
Via InvestorPlace
Tesla's Delivery Wait Times Go Up, China Wants To Secure License For Generic Version Of Pfizer's Paxlovid, India-Made iPhone Exports Surpass $2.5B: Today's Top Stories
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.